RecruitingNCT06830499

Sapien 3 Transcatheter Aortic Valve Replacement in Young Aortic Valve Stenosis Patients From China

Safety, Effectiveness and Durability of Sapien 3 Transcatheter Aortic Valve Replacement in Young Aortic Valve Stenosis Patients From China

Sponsor

Xijing Hospital

Enrollment

450 participants

Start Date

Apr 24, 2025

Study Type

OBSERVATIONAL

Conditions

AORTIC VALVE DISEASES Bicuspid Aortic Valve (BAV)

Summary

Safety, effectiveness and durability of Sapien 3 transcatheter aortic valve replacement in young aortic valve stenosis patients from China：A multi-center, retrospective and prospective, single arm, observational study

Eligibility

Min Age: 50 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a procedure called Transcatheter Aortic Valve Replacement (TAVR) for people with aortic valve diseases and bicuspid aortic valve (bav). The study is currently recruiting participants at 4 locations. People eligible for this study include aged 50 Years to 70 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURETranscatheter Aortic Valve Replacement (TAVR)

TAVR procedure was performed according to standard clinical practice. Successful vascular access, delivery and deployment of the device and successful retrieval of the delivery system will be attempted. Vascular access site will be through transfemoral on the basis of pre-procedural evaluation of access site vessel. The procedure will be performed under local or general anesthesia and per clinical practice standard.